pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 1·1 min read
save

Turn Therapeutics' eczema drug shows rapid response in mid-stage data

California biotech Turn Therapeutics shared Phase 2 data for its topical atopic dermatitis treatment that show patients experienced symptom improvement faster than usual. In an interim analysis of 50 patients, almost ...

Jun 1, 2026·read at Endpoints ↗

Bradley Burnam, Turn Therapeutics CEO June 1, 2026 08:51 AM EDT R&D Turn Ther­a­peu­tic­s' eczema drug shows rapid re­sponse in mid-stage da­ta Ayisha Sharma News Reporter Cal­i­for­nia biotech Turn Ther­a­peu­tics shared Phase 2 da­ta for its top­i­cal atopic der­mati­tis treat­ment that show pa­tients ex­pe­ri­enced symp­tom im­prove­ment faster than usu­al. In an … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
86 words · retrieved Jun 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Turn Therapeutics Inc.3
topics
Atopic Dermatitis3

related stories

  • 15h agoNovartis may cut around 130 in Switzerland while relocating biologics productionBioSpace
  • Jul 30Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continuesFierce Biotech
  • Jul 29Incyte cuts early-stage cancer drug to focus on next-gen programsBioSpace
  • Jul 27Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drugFierce Biotech
  • Jul 24Sanofi halts development of troubled immune drug in eczemaBioPharma Dive